

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462

NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557

(800.88.CIGNA)

## Herceptin Hylecta

(trastuzumab; hyaluronidase)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician Name:						t be able to respond	
Specialty:	* DEA, NPI or	TIN:	via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*				
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID: *		* Date of	* Date of Birth:	
Office Fax:			* Patient Street Address:				
Office Street Address:			City:	State:		Zip:	
City:	State:	Zip:	Patient Phone:	ie:			
Urgency:         Standard         Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication Requested:	0,000 unit/5 mL via	I 🗌 Other (p	please specify):				
Directions for use: ICD10:							
Dose:	Quan	Quantity: Duration of therapy:					
Is the patient unable to obtain o	r maintain intraven	ous (IV) access?				🗌 Yes 🗌 No	
Is this a new start or continuatio	on of therapy?	new start	] continuation of the	rapy	Start D	ate:	
(if new start) The covered altern [may require prior authorization] include medication name and st medication, including any intole	] and Trazimera (tra trength, date(s) tak	astuzumab-qyyp) [may en and for how long, and	require prior authori d what the documer	zation]. For	the alterna	atives tried, please	
(if new start) For ONE of these a which of the following applies to ☐ Patient has not tried any of tl ☐ Patient tried one of these me ☐ Patient tried one of these me ☐ Other	your patient? hese medications. edications, but it did	dn't work or didn't work v	vell enough.	-dkst], or Ti	razimera [t	:rastuzumab-qyyp]),	
(if allergic or adverse reaction) I between the requested medicat (trastuzumab-qyyp) (for example	tion and one of thes	se: Kanjinti (trastuzumat	o-anns) <mark>,</mark> Ogivri (trast				
(if documentation that reaction o	due to formulation of	difference) Please provid	de details to support				
Where will this medication				<b>h a</b> waa c			
<ul> <li>Accredo Specialty Pharmacy</li> <li>Prescriber's office stock (billi</li> <li>Other (please specify):</li> </ul>		aim form)	Home H	harmacy lealth / Hon pationally pr		n vendor ecialty pharmacy	
**Medication orders can be plac	ced with Accredo vi	a E-prescribe - Accredo	(1620 Century Cen	ter Pkwy. N	lemphis. T	N 38134-8822	

Facility and/or doctor dispensing and administering medication:         Facility Name:       State:       Tax ID#:         Address (City, State, Zip Code):       Tax ID#:							
NOTE: Per some Cigna plans, infusion of medication MUST occur in the lowest cost, medically appropriate setting							
Is this infusion occurring in a facility affiliated with hospital outpatient setting?	🗌 Yes 🗌 No						
If yes- Is this patient a candidate for re-direction to an alternate setting (such as AIS, MDO, home) with assistance of a Specialty Care Option Case Manager?  Yes No (provide medical necessity rationale):							
Is the requested medication for a chronic or long-term condition for which the prescription medication may be neces the patient?	sary for the life of ☐ Yes ☐ No						
What is your patient's diagnosis?         breast cancer       other (please specify):							
Clinical Information (if breast cancer) Does the patient have HER2-overexpressing disease?	Yes 🗌 No 🗌						
(if breast cancer) Does your patient have metastatic disease?	Yes 🗌 No 🗌						
(if breast cancer, metastatic) Will your patient use the requested medication in combination with paclitaxel (Abraxane) for first-line treatment?							
(if breast cancer, metastatic) Is/Will the requested medication be the only agent used to treat the disease at this time	e?Yes 🗌 No 🗌						
(if breast cancer, metastatic) Has your patient received one or more chemotherapy regimens in the past for this metastatic disease?							
(if breast cancer) Will the requested medication be used as adjuvant therapy?	Yes 🗌 No 🗌 Yes 🗌 No 🗌						
(if breast cancer, adjuvant) Does your patient have node positive or node negative disease? ☐ node positive ☐ node negative ☐ unknown							
(if node negative) Which best describes your patient's tumor? ☐ estrogen receptor/progesterone receptor (ER/PR)-negative ☐ estrogen receptor/progesterone receptor (ER/PR)-positive ☐ other or unknown							
(if ER/PR positive, less than 35 years old) Is your patient's tumor size greater than 2 cm? (if tumor is not greater than 2 cm) Is the patient's tumor grade 2 or 3?	Yes 🗌 No 🗌 Yes 🗌 No 🗌						
(if breast cancer, adjuvant) Will the requested medication be used in one of the following situations?							
Taxol) or docetaxel (Taxotere) ☐ as part of a treatment regimen with docetaxel (Taxotere) and carboplatin (Paraplatin) ☐ as a single agent following multi-modality anthracycline (like doxorubicin [Adriamycin], epirubicin [Ellence] or idarubicin [Idamycin PFS]) based therapy ☐ no/other							
Additional pertinent information (including disease stage, prior therapy, performance status, and names/doses/ad any agents to be used concurrently):	dmin schedule of						
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the insurer its designees may perform a routine audit and request the medical information necessary to verify the a information reported on this form.							
Prescriber Signature: Date: Date:							

## Save Time! Submit online at: https://cigna.promptpa.com

## Please fax completed form to (855) 840-1678. Urgent requests may be submitted by calling (800) 244-6224.

Our standard response time for prescription drug coverage requests is 2-4 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v010124

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005